INVESTINGMomenta Rockets After Analysts Get Bullish on Biopharma's Newest TreatmentBy Scott Van VoorhisJan 15, 2020 11:08 AM EST
PRESS RELEASESMomenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation For Nipocalimab In HDFNBy GlobeNewswireJul 28, 2020 7:15 AM EDT
PRESS RELEASESMomenta Pharmaceuticals Announces Positive Topline Data From Interim Analysis Of Phase 2 Vivacity-MG Study Of Nipocalimab (M281) In Generalized Myasthenia Gravis (gMG)By GlobeNewswireJun 15, 2020 7:05 AM EDT
PRESS RELEASESMomenta Pharmaceuticals Announces Date Of First Quarter 2020 Financial Results Conference Call And WebcastBy GlobeNewswireApr 23, 2020 8:00 AM EDT
PRESS RELEASESMomenta Provides Corporate Update Amid COVID-19 PandemicBy GlobeNewswireApr 2, 2020 7:30 AM EDT
PRESS RELEASESMomenta Pharmaceuticals To Webcast Presentation At The Cowen 40th Annual Health Care ConferenceBy GlobeNewswireFeb 19, 2020 8:00 AM EST
PRESS RELEASESMomenta Pharmaceuticals Announces Date Of Fourth Quarter And Year End 2019 Financial Results Conference Call And WebcastBy GlobeNewswireFeb 12, 2020 8:00 AM EST
INVESTINGMomenta Rockets After Analysts Get Bullish on Biopharma's Newest TreatmentBy Scott Van VoorhisJan 15, 2020 11:08 AM EST
STOCKSTeva shares fall as FDA OKs another generic version of multiple sclerosis drugBy Armie Margaret LeeFeb 13, 2018 5:33 PM EST
STOCKSStates Target Mylan President, Emcure Exec in Generic Drug LawsuitBy Armie Margaret LeeNov 1, 2017 4:59 PM EDT
MERGERS AND ACQUISITIONSTeva Must Clear Three Big Hurdles to Have a Hope of ReclaimBy William McConnellAug 21, 2017 9:42 AM EDT
STOCKSTeva Shares Are Taking a Beating and Dragging Down the Entire Drug SectorBy Kinsey GrantAug 3, 2017 11:46 AM EDT
MERGERS AND ACQUISITIONSAmneal, Impax, Other Struggling Generics Face M&A DilemmaBy William McConnellJun 13, 2017 12:07 PM EDT
STOCKSAnalysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and MoreBy TheStreet StaffFeb 22, 2017 8:03 AM EST
STOCKSSarepta's priority review voucher leads biotech moversBy Alicia McElhaneyFeb 21, 2017 10:09 AM EST
STOCKSPremarket biotech movers: Mylan, Momenta Pharmaceuticals, Seres TherapeuticsBy Armie Margaret LeeJan 31, 2017 9:27 AM EST
STOCKSMedtronic, Insys Among Day's Biggest Losers, Trump Continues to Pressure Healthcare SectorBy Vicky HuangNov 22, 2016 5:24 PM EST
MARKETSMomenta Pharmaceuticals (MNTA) Stock Surges, Barclays UpgradesBy Rachel AldrichOct 11, 2016 2:45 PM EDT
STOCKSMomenta, coherus biosciences are both good options in the biosimilar spaceBy Robert WassermanOct 5, 2016 9:14 AM EDT
INVESTINGVisium hedge fund partner charged in insider trading caseBy Keith GriffithJun 16, 2016 1:45 PM EDT
MARKETSInsider Trading Alert - STS, RRGB And MNTA Traded By InsidersBy TheStreet WireMay 24, 2016 10:15 AM EDT
MARKETSMomenta Pharmaceuticals (MNTA) Is Strong On High Volume TodayBy TheStreet WireApr 4, 2016 10:03 AM EDT
OPINION6 biotech stocks under $10 to trade for big breakoutsBy Roberto PedoneMar 23, 2016 8:38 AM EDT
MARKETSInsider Trading Alert - GST, MNTA And ZEN Traded By InsidersBy TheStreet WireFeb 25, 2016 10:15 AM EST
